TY  - JOUR
AU  - Guntschnig, Sonja
AU  - Antoniadis, Vasilis
AU  - Falamic, Slaven
AU  - Kovačević, Tijana
AU  - Kurczewska-Michalak, Marta
AU  - Miljković, Branislava
AU  - Olearova, Anna
AU  - Sviestina, Inese
AU  - Szucs, Attila
AU  - Bampali, Konstantina
AU  - Tiszai, Zita
AU  - Volmer, Daisy
AU  - Wiela-Hojeńska, Anna
AU  - Fialova, Daniela
AU  - Vlcek, Jiri
AU  - Stuhec, Matej
AU  - Hogg, Anita
AU  - Scott, Michael
AU  - Stewart, Derek
AU  - Mair, Alpana
AU  - Ravera, Silvia
AU  - Lery, François-Xavier
AU  - Kardas, Przemysław
PY  - 2023
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/4984
AB  - Clinical pharmacy as an area of practice, education and research started developing around the 1960s when pharmacists across the globe gradually identified the need to focus more on ensuring the appropriate use of medicines to improve patient outcomes rather than being engaged in manufacturing and supply. Since that time numerous studies have shown the positive impact of clinical pharmacy services (CPS). The need for wider adoption of CPS worldwide becomes urgent, as the global population ages, and the prevalence of polypharmacy as well as shortage of healthcare professionals is rising. At the same time, there is great pressure to provide both high-quality and cost-effective health services. All these challenges urgently require the adoption of a new paradigm of healthcare system architecture. One of the most appropriate answers to these challenges is to increase the utilization of the potential of highly educated and skilled professionals widely available in these countries, i.e., pharmacists, who are well positioned to prevent and manage drug-related problems together with ensuring safe and effective use of medications with further care relating to medication adherence. Unfortunately, CPS are still underdeveloped and underutilized in some parts of Europe, namely, in most of the Central and Eastern European (CEE) countries. This paper reviews current situation of CPS development in CEE countries and the prospects for the future of CPS in that region.
PB  - Frontiers Media SA
T2  - Frontiers in Pharmacology
T1  - Recommendations for wider adoption of clinical pharmacy in Central and Eastern Europe in order to optimise pharmacotherapy and improve patient outcomes
VL  - 14
DO  - 10.3389/fphar.2023.1244151
ER  - 

@article{
author = "Guntschnig, Sonja and Antoniadis, Vasilis and Falamic, Slaven and Kovačević, Tijana and Kurczewska-Michalak, Marta and Miljković, Branislava and Olearova, Anna and Sviestina, Inese and Szucs, Attila and Bampali, Konstantina and Tiszai, Zita and Volmer, Daisy and Wiela-Hojeńska, Anna and Fialova, Daniela and Vlcek, Jiri and Stuhec, Matej and Hogg, Anita and Scott, Michael and Stewart, Derek and Mair, Alpana and Ravera, Silvia and Lery, François-Xavier and Kardas, Przemysław",
year = "2023",
abstract = "Clinical pharmacy as an area of practice, education and research started developing around the 1960s when pharmacists across the globe gradually identified the need to focus more on ensuring the appropriate use of medicines to improve patient outcomes rather than being engaged in manufacturing and supply. Since that time numerous studies have shown the positive impact of clinical pharmacy services (CPS). The need for wider adoption of CPS worldwide becomes urgent, as the global population ages, and the prevalence of polypharmacy as well as shortage of healthcare professionals is rising. At the same time, there is great pressure to provide both high-quality and cost-effective health services. All these challenges urgently require the adoption of a new paradigm of healthcare system architecture. One of the most appropriate answers to these challenges is to increase the utilization of the potential of highly educated and skilled professionals widely available in these countries, i.e., pharmacists, who are well positioned to prevent and manage drug-related problems together with ensuring safe and effective use of medications with further care relating to medication adherence. Unfortunately, CPS are still underdeveloped and underutilized in some parts of Europe, namely, in most of the Central and Eastern European (CEE) countries. This paper reviews current situation of CPS development in CEE countries and the prospects for the future of CPS in that region.",
publisher = "Frontiers Media SA",
journal = "Frontiers in Pharmacology",
title = "Recommendations for wider adoption of clinical pharmacy in Central and Eastern Europe in order to optimise pharmacotherapy and improve patient outcomes",
volume = "14",
doi = "10.3389/fphar.2023.1244151"
}

Guntschnig, S., Antoniadis, V., Falamic, S., Kovačević, T., Kurczewska-Michalak, M., Miljković, B., Olearova, A., Sviestina, I., Szucs, A., Bampali, K., Tiszai, Z., Volmer, D., Wiela-Hojeńska, A., Fialova, D., Vlcek, J., Stuhec, M., Hogg, A., Scott, M., Stewart, D., Mair, A., Ravera, S., Lery, F.,& Kardas, P.. (2023). Recommendations for wider adoption of clinical pharmacy in Central and Eastern Europe in order to optimise pharmacotherapy and improve patient outcomes. in Frontiers in Pharmacology
Frontiers Media SA., 14.
https://doi.org/10.3389/fphar.2023.1244151

Guntschnig S, Antoniadis V, Falamic S, Kovačević T, Kurczewska-Michalak M, Miljković B, Olearova A, Sviestina I, Szucs A, Bampali K, Tiszai Z, Volmer D, Wiela-Hojeńska A, Fialova D, Vlcek J, Stuhec M, Hogg A, Scott M, Stewart D, Mair A, Ravera S, Lery F, Kardas P. Recommendations for wider adoption of clinical pharmacy in Central and Eastern Europe in order to optimise pharmacotherapy and improve patient outcomes. in Frontiers in Pharmacology. 2023;14.
doi:10.3389/fphar.2023.1244151 .

Guntschnig, Sonja, Antoniadis, Vasilis, Falamic, Slaven, Kovačević, Tijana, Kurczewska-Michalak, Marta, Miljković, Branislava, Olearova, Anna, Sviestina, Inese, Szucs, Attila, Bampali, Konstantina, Tiszai, Zita, Volmer, Daisy, Wiela-Hojeńska, Anna, Fialova, Daniela, Vlcek, Jiri, Stuhec, Matej, Hogg, Anita, Scott, Michael, Stewart, Derek, Mair, Alpana, Ravera, Silvia, Lery, François-Xavier, Kardas, Przemysław, "Recommendations for wider adoption of clinical pharmacy in Central and Eastern Europe in order to optimise pharmacotherapy and improve patient outcomes" in Frontiers in Pharmacology, 14 (2023),
https://doi.org/10.3389/fphar.2023.1244151 . .

TY  - JOUR
AU  - Andronis, Christos
AU  - Silva, João
AU  - Lekka, Eftychia
AU  - Virvilis, Vassilis
AU  - Carmo, Helena
AU  - Bampali, Konstantina
AU  - Ernst, Margot
AU  - Hu, Yang
AU  - Loryan, Irena
AU  - Richard, Jacques
AU  - Carvalho, Félix
AU  - Savić, Miroslav
PY  - 2020
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/3613
AB  - Drug-induced Mood- and Cognition-related adverse events (MCAEs) are often only detected during the clinical trial phases of drug development, or even after marketing, thus posing a major safety concern and a challenge for both pharmaceutical companies and clinicians. To fill some gaps in the understanding and elucidate potential biological mechanisms of action frequently associated with MCAEs, we present a unique workflow linking observational population data with the available knowledge at molecular, cellular, and psychopharmacology levels. It is based on statistical analysis of pharmacovigilance reports and subsequent signaling pathway analyses, followed by evidence-based expert manual curation of the outcomes. Our analysis: (a) ranked pharmaceuticals with high occurrence of such adverse events (AEs), based on disproportionality analysis of the FDA Adverse Event Reporting System (FAERS) database, and (b) identified 120 associated genes and common pathway nodes possibly underlying MCAEs. Nearly two-thirds of the identified genes were related to immune modulation, which supports the critical involvement of immune cells and their responses in the regulation of the central nervous system function. This finding also means that pharmaceuticals with a negligible central nervous system exposure may induce MCAEs through dysregulation of the peripheral immune system. Knowledge gained through this workflow unravels putative hallmark biological targets and mediators of drug-induced mood and cognitive disorders that need to be further assessed and validated in experimental models. Thereafter, they can be used to substantially improve in silico/in vitro/in vivo tools for predicting these adversities at a preclinical stage.
PB  - Springer Nature Switzerland
T2  - Archives of Toxicology
T1  - Molecular basis of mood and cognitive adverse events elucidated via a combination of pharmacovigilance data mining and functional enrichment analysis
VL  - 94
IS  - 8
SP  - 2829
EP  - 2845
DO  - 10.1007/s00204-020-02788-1
ER  - 

@article{
author = "Andronis, Christos and Silva, João and Lekka, Eftychia and Virvilis, Vassilis and Carmo, Helena and Bampali, Konstantina and Ernst, Margot and Hu, Yang and Loryan, Irena and Richard, Jacques and Carvalho, Félix and Savić, Miroslav",
year = "2020",
abstract = "Drug-induced Mood- and Cognition-related adverse events (MCAEs) are often only detected during the clinical trial phases of drug development, or even after marketing, thus posing a major safety concern and a challenge for both pharmaceutical companies and clinicians. To fill some gaps in the understanding and elucidate potential biological mechanisms of action frequently associated with MCAEs, we present a unique workflow linking observational population data with the available knowledge at molecular, cellular, and psychopharmacology levels. It is based on statistical analysis of pharmacovigilance reports and subsequent signaling pathway analyses, followed by evidence-based expert manual curation of the outcomes. Our analysis: (a) ranked pharmaceuticals with high occurrence of such adverse events (AEs), based on disproportionality analysis of the FDA Adverse Event Reporting System (FAERS) database, and (b) identified 120 associated genes and common pathway nodes possibly underlying MCAEs. Nearly two-thirds of the identified genes were related to immune modulation, which supports the critical involvement of immune cells and their responses in the regulation of the central nervous system function. This finding also means that pharmaceuticals with a negligible central nervous system exposure may induce MCAEs through dysregulation of the peripheral immune system. Knowledge gained through this workflow unravels putative hallmark biological targets and mediators of drug-induced mood and cognitive disorders that need to be further assessed and validated in experimental models. Thereafter, they can be used to substantially improve in silico/in vitro/in vivo tools for predicting these adversities at a preclinical stage.",
publisher = "Springer Nature Switzerland",
journal = "Archives of Toxicology",
title = "Molecular basis of mood and cognitive adverse events elucidated via a combination of pharmacovigilance data mining and functional enrichment analysis",
volume = "94",
number = "8",
pages = "2829-2845",
doi = "10.1007/s00204-020-02788-1"
}

Andronis, C., Silva, J., Lekka, E., Virvilis, V., Carmo, H., Bampali, K., Ernst, M., Hu, Y., Loryan, I., Richard, J., Carvalho, F.,& Savić, M.. (2020). Molecular basis of mood and cognitive adverse events elucidated via a combination of pharmacovigilance data mining and functional enrichment analysis. in Archives of Toxicology
Springer Nature Switzerland., 94(8), 2829-2845.
https://doi.org/10.1007/s00204-020-02788-1

Andronis C, Silva J, Lekka E, Virvilis V, Carmo H, Bampali K, Ernst M, Hu Y, Loryan I, Richard J, Carvalho F, Savić M. Molecular basis of mood and cognitive adverse events elucidated via a combination of pharmacovigilance data mining and functional enrichment analysis. in Archives of Toxicology. 2020;94(8):2829-2845.
doi:10.1007/s00204-020-02788-1 .

Andronis, Christos, Silva, João, Lekka, Eftychia, Virvilis, Vassilis, Carmo, Helena, Bampali, Konstantina, Ernst, Margot, Hu, Yang, Loryan, Irena, Richard, Jacques, Carvalho, Félix, Savić, Miroslav, "Molecular basis of mood and cognitive adverse events elucidated via a combination of pharmacovigilance data mining and functional enrichment analysis" in Archives of Toxicology, 94, no. 8 (2020):2829-2845,
https://doi.org/10.1007/s00204-020-02788-1 . .